A carregar...
Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma
Anti-angiogenic therapy is a promising therapeutic strategy for the highly vascular and malignant brain tumor, glioblastoma (GBM), although current clinical trials have failed to demonstrate an extension in overall survival. The small molecule tyrosine kinase inhibitor axitinib that targets vascular...
Na minha lista:
| Publicado no: | J Neurooncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4751887/ https://ncbi.nlm.nih.gov/pubmed/25213669 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1612-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|